Holen Sie sich die Stockscreener-App
8.855
10.41%
0.835
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet reports 57% IGA success at Week 52 - grafa.com
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance Singapore
Inflammatory acne lesions fell 77% over 52 weeks - Stock Titan
Warrants carry a 9.99% ownership cap in a passive Sagimet Biosciences (SGMT) stake. - Stock Titan
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance UK
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewswire
Sagimet raised about $115 million, with an acne drug trial among its planned uses. - Stock Titan
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Yahoo Finance UK
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Yahoo Finance
Sagimet Biosciences (Nasdaq:SGMT)Stock Analysis - Simply Wall Street
Sagimet prices $115 million stock offering at $10 per share By Investing.com - Investing.com Nigeria
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data - Yahoo Finance
Stock sales through Leerink are suspended at Sagimet Biosciences (SGMT). - Stock Titan
Sagimet Reports 52-Week Denifanstat Acne Trial Results - grafa.com
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell - Yahoo Finance
Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants - TradingView
Sagimet Biosciences Announces Pricing of $115.0 Million - globenewswire.com
About $115 million from a share sale is expected to help fund Sagimet's acne trial and other drug work. - Stock Titan
A 240-patient open-label acne extension yields 52-week results for Sagimet (SGMT). - Stock Titan
Sagimet Biosciences Raises $115 Million in Stock Offering - Intellectia AI
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - GlobeNewswire Inc.
A 52-week acne trial in China showed further improvement across all secondary measures. - Stock Titan
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Nigeria
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com Canada
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com India
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8 - marketscreener.com
Barclays upgrades Sagimet stock rating on acne drug potential - investing.com
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com India
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Canada
Barclays upgrades Sagimet stock rating on acne drug potential - Investing.com
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - Yahoo Finance
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of - GlobeNewswire
Sagimet (SGMT) Earnings Report: Profit Per Share Clears Its Benchmark in Latest Trading - vinanet.vn
Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Sagimet Biosciences Inc.Series A Common Stock (SGMT) Stock Price, News, Quote & History - FinancialContent
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - Yahoo Finance
Three New Hires Get Stock Options That Vest Over Four Years at Sagimet - Stock Titan
0.49%
6.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):